Comments on: Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma–4th approved indication for toripalimab

Comments on: Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma–4th approved indication for toripalimab - 关于君实生物 //www.axcessimc.com/en/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e7%94%a8%e4%ba%8e%e9%bc%bb%e5%92%bd%e7%99%8c%e4%b8%80%e7%ba%bf%e6%b2%bb/ 创新疗法的发现、开发和商业化的生物制药公司。 Thu, 12 Jan 2023 10:17:52 +0000 hourly 1 https://wordpress.org/?v=6.7.2